CEO Kym Anthony Discusses 2017 Miles Stones and Product Developments

Ottawa, ONT , Nov. 13, 2017 -- Kym Anthony CEO of Avivagen, Inc. (“Company”) (TSX-V:VIV), (OTCPink:CHEXF) interviews with host Everett Jolly on the Uptick Network Stock Day Podcast. In the first half of the interview, Mr. Anthony discusses the ramping up of moving the Company from development to commercialization in the Philippians. He discusses the success anti-inflammatory effects of the OxC-Beta compound and the process of monetizing revenues from the Company’s products. Furthermore, Mr. Anthony briefly touches on the process of taking on additional major global feed suppliers to help expand the Company.

To listen to the full interview please click here or the following link: https://upticknewswire.com/featured-interview-ceo-kym-anthony-of-avivagen-inc-otcpink-chexf-2/

About Avivagen
Avivagen Inc. is a life sciences corporation that has developed a scientifically-proven product for replacing antibiotics in livestock feeds and to otherwise benefit human and animal health. Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

About Vivamune™ Health Chews (Vivamune)
Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient: OxC-beta™ compound, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the US. For more information, visit www.vivamunehealth.com. 

About OxC-beta™ Technology (OxC-beta) 
OxC-beta, Avivagen’s proprietary formulation of fully oxidized β-carotene exhibits promising health benefits in animals and potentially humans. Laboratory studies and animal trials that have established the novel, underlying basis of OxC-beta’s immune function support have been reported in peer-reviewed scientific publications. 

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Without limiting the generality of the foregoing, statements regarding Vivamune’s ability to increase its brand awareness or market share, the potential effects or reach of the marketing campaigns described above and any statements about the potential for use of Avivagen’s products in humans and animals are all forward looking statements.  Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, the following: whether Avivagen’s relaunch of its Vivimune product will be successful, its marketing campaign may not have the desired effects, whether Vivimune can deliver the benefits described in this press release to any or all dogs, if at all, whether Vivimune can promote or support dogs’ skin, joints and gut health, normal mobility, or support dogs with occasional stiffness, or maintain healthy hip and joint function, relieve stiffness, promote healthy skin and soothe skin-related issues associated with seasonal allergies in any or all dogs, if at all, Avivagen’s ability to continue as a going concern, if Avivagen can commercialize products to replace the antibiotics used in livestock feeds, if it can accelerate market access and the commercial uptake of its OxC-beta™ Livestock product and its Vivimune Health Chews supplement, whether OxC-beta™ will continue to show promising benefits for humans and animals alike; whether Avivagen can continue to protect its intellectual property; if Avivagen’s innovative products have the potential to eliminate the use of antibiotics as growth promoters in livestock feed. 

Readers should also refer to the risk factors in Avivagen’s Annual Information Form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: Uptick Newswire

For more information: 
Avivagen Inc.
Drew Basek, Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: [email protected]

Kym Anthony, Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com